secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040176
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS partner GenFleet doses first patient in Phase Ib/II combo trial of GFH009 + BRUKINSA for DLBCL
--------------------------------------------------------------------------------

- GenFleet entered clinical trial collaboration with BeiGene for GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib).
- First patient dosed in open-label, single-arm, multi-center Phase Ib/II trial for relapsed/refractory DLBCL in China.
- Trial evaluates safety and efficacy of the combination therapy; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465924040176/0001104659-24-040176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465924040176/tm2410063d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer